SIRT6 and metabolic dysfunction-associated steatotic liver disease: In parallel, SIRT6 could increase the activity of long-chain acyl-CoA synthase 5 (ACSL5) by deacetylating K98, K361 and K367 and promote fatty acid β-oxidation, thereby increasing the cellular lipid utilization and ultimately resisting the NAFLD process [100].